Ciprofibrate increases cholesteryl ester transfer protein gene expression and the indirect reverse cholesterol transport to the liver.

Lipids in Health and Disease
Eliete J B BighettiHelena C F Oliveira

Abstract

CETP is a plasma protein that modulates atherosclerosis risk through its HDL-cholesterol reducing action. The aim of this work was to examine the effect of the PPARalpha agonist, ciprofibrate, on the CETP gene expression, in the presence and absence of apolipoprotein (apo) CIII induced hypertriglyceridemia, and its impact on the HDL metabolism. Mice expressing apo CIII and/or CETP and non-transgenic littermates (CIII, CIII/CETP, CETP, non-Tg) were treated with ciprofibrate during 3 weeks. Drug treatment reduced plasma triglycerides (30-43%) and non-esterified fatty acids (19-47%) levels. Cholesterol (chol) distribution in plasma lipoprotein responses to ciprofibrate treatment was dependent on the genotypes. Treated CIII expressing mice presented elevation in VLDL-chol and reduction in HDL-chol. Treated CETP expressing mice responded with reduction in LDL-chol whereas in non-Tg mice the LDL-chol increased. In addition, ciprofibrate increased plasma post heparin lipoprotein lipase activity (1.3-2.1 fold) in all groups but hepatic lipase activity decreased in treated CETP and non-Tg mice. Plasma CETP activity and liver CETP mRNA levels were significantly increased in treated CIII/CETP and CETP mice (30-100%). Kinetic studies with ...Continue Reading

References

Jan 24, 1992·Biochimica Et Biophysica Acta·B StaelsJ Auwerx
Dec 1, 1991·The Journal of Clinical Investigation·C J MannB E Bihain
Jan 1, 1986·Methods in Enzymology·C Ehnholm, T Kuusi
Feb 1, 1985·The Journal of Clinical Investigation·C S WangP Alaupovic
Nov 1, 1995·Journal of Internal Medicine·J KahriM R Taskinen
Jul 1, 1996·Atherosclerosis·G Turpin, E Bruckert
Nov 10, 1998·Circulation·B StaelsJ C Fruchart
Feb 23, 2000·The Journal of Clinical Investigation·Y Luo, A R Tall
May 16, 2000·Arteriosclerosis, Thrombosis, and Vascular Biology·A R TallD Silver
Jan 4, 2003·The Journal of Biological Chemistry·Pablo MardonesAttilio Rigotti
Jan 9, 2003·Journal of Lipid Research·Patrícia M CazitaHelena C F Oliveira
Feb 18, 2003·Arteriosclerosis, Thrombosis, and Vascular Biology·Philip J BarterAlan R Tall
Mar 15, 2003·Arteriosclerosis, Thrombosis, and Vascular Biology·Sung-Joon LeeFrank M Sacks
Nov 11, 2003·Canadian Journal of Physiology and Pharmacology·Sukhinder Kaur Cheema, Fariborz Rashid-Kolvear
Jan 29, 2005·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Jairo A BertiHelena C F Oliveira
Sep 2, 2006·Arteriosclerosis, Thrombosis, and Vascular Biology·Marit WesterterpPatrick C N Rensen
Feb 3, 2007·Arteriosclerosis, Thrombosis, and Vascular Biology·Christopher HarderRuth McPherson
May 26, 2007·Journal of Lipid Research·Caroline C van der HoogtPatrick C N Rensen

❮ Previous
Next ❯

Citations

Apr 22, 2014·The Journal of Nutritional Biochemistry·Helena F RaposoHelena C F Oliveira
Jul 15, 2015·Nutrients·Alina Adriana IvanescuAlfredo García-Layana
Mar 6, 2012·The Quarterly Review of Biology·Angelique P Corthals
Feb 23, 2019·International Journal of Environmental Research and Public Health·Alejandro Marín-MedinaJuan C Díaz-Zagoya

❮ Previous
Next ❯

Datasets Mentioned

BETA
U71187

Methods Mentioned

BETA
transgenic
PCR
electrophoresis

Software Mentioned

Scion Image analysis

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.